Churg-Strauss syndrome/Eosinophilic Granulomatosis with Polyangiitis (EGPA)

EGPA, or Churg-Strauss Syndrome, is the inflammation of blood vessels (vasculitis), clustering of white blood cells, and development of granulomas (inflammatory nodular lesions). EGPA affects multiple organs including the lungs, kidneys, GI tract, nerves, skin, and heart.

Asthma, hay fever, weight loss, joint and muscle pain, fatigue, cough, benign growths in the nose (polyps), numbness and tingling, rash, abdominal pain, blood in urine or stools, and shortness of breath.

Asthma, kidney disease, sinusitis, polyneuropathy, and myocarditis.

A history of asthma or nasal allergies is the main risk factor for developing EGPA, and typically precedes EGPA onset by 5 to 9 years.

• Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis (2023)
• Familial Association of Granulomatosis With Polyangiitis: A Case-Based Review of Literature (2023)
• Biologics for eosinophilic granulomatosis with polyangiitis (2023)
• Neurological impact of eosinophilic granulomatosis with polyangiitis (2022)
• Environmental factors influencing the risk of ANCA-associated vasculitis (2022)

Tune in to this webcast to hear expert faculty as they discuss:

• EGPA diagnosis and patient assessment
• Relating EGPA pathophysiology to treatment targets
• The latest clinical trial data evaluating new and emerging therapies
• Strategies for effective multidisciplinary management
• Ask the Expert Q&A